Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with SBRT in Inoperable HCC
NCT04913480Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by The University of Hong Kong. Status: unknown.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04913480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913480.